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Abstract
The envelope spike of HIV-1 employs a ‘glycan shield’ to protect itself from antibody-mediated 
neutralization. Paradoxically, however, potent broadly neutralizing antibodies (bnAbs) have been 
isolated which target this shield. The unusually high glycan density on the gp120 subunit limits 
processing during biosynthesis, leaving a region of under-processed oligomannose-type structures 
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which is a primary target of these bnAbs. Here we investigate the contribution of individual 
glycosylation sites to formation of this so-called intrinsic mannose patch. Deletion of individual 
sites has a limited effect on the overall size of the intrinsic mannose patch but leads to changes in 
the processing of neighboring glycans. These structural changes are largely tolerated by a panel of 
glycan-dependent bnAbs targeting these regions, indicating a degree of plasticity in their 
recognition. These results support the intrinsic mannose patch as a stable target for vaccine design.
Keywords
HIV; N-linked glycosylation; oligomannose; broadly neutralizing antibodies
Introduction
The envelope spike of HIV-1 (Env) orchestrates host cell entry and is the primary target for 
neutralizing antibodies. Env is a heavily glycosylated molecule, with N-linked glycans 
accounting for approximately half of the mass of gp120 (ref.1). These glycans provide 
essential roles in protein folding and infectivity2,3 and also act to shield the underlying 
protein epitopes from recognition by neutralizing antibodies4. The N-linked glycans of 
gp120 are synthesized using the host cell glycosylation machinery. However, 
characterization of the glycoforms present has identified a significant population of 
unprocessed oligomannose-type glycans on gp120, termed the intrinsic mannose patch, 
which are not usually observed at high abundance on secreted mammalian glycoproteins5-8. 
This divergence from host cell glycosylation is thought to derive from the exceptionally high 
density of glycans on the outer domain of gp120, which restricts access to ER and Golgi α-
mannosidases and prevents the subsequent processing reactions that typically lead to 
synthesis of complex-type glycans7.
The ‘non-self’ nature of these oligomannose glycans suggests they could represent a 
potentially immunogenic target, and indeed a number of broadly neutralizing anti-HIV-1 
antibodies (bnAbs) have been isolated which incorporate gp120 glycans as part of their 
epitope9-12. 2G12 was the first such antibody to be described, which exploits an unusual 
domain-exchanged configuration and binds terminal Manα1→2Man residues on the surface 
of gp120 (ref.13-15). More recently, a collection of bnAbs has been described which 
recognize dual protein-glycan epitopes9,11,12,16-25. A number of these, including PGT121, 
PGT128 and PGT135, have been demonstrated to be dependent on the outer domain glycan 
at N332, with this site being referred to as a ‘supersite’ of immune vulnerability9,17,19,26,27. 
Comparison of these bnAbs with those targeting alternative epitopes on gp120, including the 
CD4-binding site (CD4bs) or membrane-proximal external region (MPER) reveal that they 
offer some of the highest potencies of neutralization9. Furthermore, the different bnAbs 
derive from various combinations of antibody germline genes, indicating that there are 
multiple solutions for targeting this region9,20,28.
Passive transfer of such bnAbs confers resistance to viral challenge in macaque studies29-31, 
and thus efforts are being focused to elucidate their precise epitopes, with the aim of 
designing immunogens capable of eliciting such neutralizing responses through 
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vaccination32. However, a concern regarding the targeting of gp120 glycans relates to the 
shifting nature of the glycan shield, with additions and deletions of glycan sites being a 
common response by HIV-1 to antibody-mediated selection pressure33,34. Here we 
investigate the integrity and robustness of the oligomannose population of gp120 in the face 
of sequence variation, and determine the consequences of glycan site mutation on the 
formation of bnAb epitopes. Systematic site-directed mutagenesis of the potential N-
glycosylation sites (PNGSs) of gp120BaL, demonstrates widespread conservation of the 
oligomannose population, although unexpectedly large perturbations are observed upon loss 
of certain PNGSs. Structural modeling of the glycan shield reveals protein–glycan and 
glycan–glycan packing that suggests an explanation for these observations and rationalizes 
the characteristic processing observed at different glycosylation sites. While it is 
demonstrated that mutation of sites involved in glycan clusters can lead to subtle ‘bystander’ 
processing effects, these changes can largely be tolerated by a panel of bnAbs. The 
conservation and persistence of oligomannose-type glycans, despite glycan site deletion, 
suggests that the intrinsic mannose patch is likely to be an important component of an 
effective vaccine.
Results
Resilience of the mannose patch to glycan site deletion
Site-specific glycosylation analysis of recombinant gp120 indicates that, depending on the 
isolate, up to half of the PNGSs are occupied by oligomannose-type glycans1,5,6,35-37. Given 
the perceived role of glycan density in driving the formation of the intrinsic mannose patch, 
it is conceivable that the loss of a single glycan could have a widespread effect on many near 
and distant glycans by changing the processing state of its neighbors. In this scenario, 
glycans that would otherwise be protected by a neighboring glycan become exposed and are 
processed by cellular enzymes to complex-type structures. We therefore sought to 
investigate the role of an individual glycan site in the formation of the intrinsic mannose 
patch by site-directed mutagenesis of all 23 gp120 PNGSs of the clade B isolate, BaL.
Asparagine residues within the consensus sequence Asn-X-Ser/Thr (where X is any amino 
acid except Pro) were mutated to alanine. The gp120 constructs were then expressed 
transiently in 293T cells and purified by nickel affinity chromatography. Expression of the 
panel of gp120BaL mutants was performed in parallel to minimize the intrinsic variation of 
glycosylation (Supplementary Fig. 1; Supplementary Table 1). Following resolution by 
SDS-PAGE, N-linked glycans were released from monomeric gp120 by treatment with 
protein N-glycosidase F (PNGase F) and analyzed by hydrophilic interaction liquid 
chromatography-ultra performance liquid chromatography (HILIC-UPLC). HILIC-UPLC 
was used as it offers a quantitative method for analysis of complex glycan mixtures that is 
not biased by the glycan composition. Integration of the HILIC-UPLC spectra together with 
digestions of the fluorescently labeled glycan pool with Endo H enabled the quantitation of 
oligomannose species.
The HILIC-UPLC chromatogram of the glycans from wild-type gp120BaL reveals a mixture 
of complex- and oligomannose-type glycans (Fig. 1a). Many of the glycosylation sites on 
gp120BaL predicted to be of the oligomannose-type1,35,37,38 (Fig. 1b) show a high degree of 
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conservation across different clades (Fig. 1c). Changes in the total abundance of 
oligomannose-type glycans (relative to wild type) were calculated from the HILIC-UPLC 
data (Fig. 1d; Supplementary Fig. 2; Supplementary Table 2). Overall, the direction of 
change corresponded well with the predicted glycan species at each site; loss of predicted 
complex sites showed an increased relative abundance of oligomannose-type glycans, while 
loss of predicted sites of oligomannose generally resulted in lower relative abundances of 
oligomannose-type glycans. For a few PNGS-deletions, for example N386 and N392, larger 
than expected losses of oligomannose were observed (14% and 15% decreases, 
respectively). These PNGSs may represent sites that normally impede the access of α-
mannosidases to neighboring sites, whereby their removal facilitates greater access and 
trimming of surrounding glycans.
Thus while some mutations lead to larger than expected losses in oligomannose, the 
majority of PNGS-deletions had a very limited impact on the size of the mannose patch. 
Several double PNGS-deletion mutants were also analyzed. No dramatic decreases in the 
overall abundance of oligomannose were observed, with the N295A/N386A double mutant 
showing the largest effect with a loss of 27% (Fig. 1d; Supplementary Table 2). Since the 
BaL isolate lacks the N160 and N276 glycans, which are highly conserved and have been 
shown to be important for recognition by several bnAbs9,16,39, we also assessed the impact 
of these glycans by introducing them into the wild-type BaL sequence. These glycans were 
found to have a limited impact on the size of the mannose patch, either individually or when 
combined (Supplementary Table 2). Overall these data demonstrate the stability of the size 
of the mannose patch in the face of glycan site deletion.
Glycan-glycan interactions restrict glycan processing
While the overall size of the mannose patch remained relatively unperturbed upon deletion 
of individual PNGSs, closer inspection of the HILIC-UPLC traces revealed that the 
abundances of the individual oligomannose species (Man5-9GlcNAc2) varied more 
considerably. Figure 1d shows the change in levels of Man9GlcNAc2, which displayed the 
greatest sensitivity to removal of PNGSs (Fig. 1d; Supplementary Table 2). A decrease of 
over 25% was observed for 9 sites: N130, N262, N295, N339, N356, N386, N392 and 
N448. These contrasting effects on the overall abundance of oligomannose and 
Man9GlcNAc2 alone can be reconciled by the changing proportions of the other 
oligomannose species. For example at the N295 site no change in the overall level of 
oligomannose was detectable, however a large decrease in Man9GlcNAc2 was apparent. 
This decrease in Man9GlcNAc2 was offset by an increase in Man6-8GlcNAc2, suggesting a 
redistribution of oligomannose species across the intrinsic mannose patch that goes beyond a 
simple loss of glycans from the N295 site.
The apparent redistribution of glycoforms upon PNGS-deletion, from larger oligomannose-
type glycans to smaller oligomannose species, indicates that individual PNGSs have a role 
in influencing the processing of glycans at neighboring sites. To understand this 
phenomenon at the structural level, a model of a fully glycosylated gp120BaL trimer was 
constructed based on the crystal structure of a BG505 SOSIP.664 gp140 trimer21 (Fig. 2a). 
Man8GlcNAc2 glycans were incorporated at sites of predicted oligomannose-type glycans, 
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while Man5GlcNAc2 was chosen as a representative mid-sized glycan that is commonly 
found alongside complex-type glycans at gp120 glycosylation sites (Supplementary Fig. 3). 
The glycosylated model demonstrates the uniquely high density of glycans on the surface of 
Env that represents a significant barrier to processing by glycosidases and 
glycosyltransferases.
Plotting of the changes in Man9GlcNAc2 abundance on to the gp120 monomer defined a 
region of high glycan density that was sensitive to deletion of local PNGSs (Fig. 2b). This 
region mapped to the outer domain of gp120 and is consistent with previous observations of 
the intrinsic mannose patch1,5,6,35-37. Closer inspection of individual PNGSs within this 
region revealed sites of glycan clusters with two or more glycans positioned in very close 
proximity. For example one such cluster involves the N386 and N392 glycans, in which the 
Asn Cα atoms are positioned approximately 12 Å apart. Deletion of the N392 glycan led to 
an overall decrease in oligomannose abundance of 15% (Fig. 1d and Supplementary Table 
2), primarily driven by losses of Man9GlcNAc2 and Man8GlcNAc2 (32% and 22% relative 
to wild-type, respectively; Fig. 2c). Another cluster was identified based around the N295 
glycan, which occupies a central location between the N332 and N448 sites. While loss of 
the N295 glycan had no overall effect on the total abundance of oligomannose, it resulted in 
a 28% decrease in Man9GlcNAc2 (Fig. 2c; Supplementary Table 2).
Glycan–glycan interactions within these tight clusters not only suggest an explanation for 
the limited processing of these glycans, but could rationalize the more widespread changes 
to glycan processing observed upon removal of a single glycan. It is likely that removal of a 
glycan within such a cluster increases mobility and accessibility to its neighboring glycan(s), 
thereby increasing the level of processing that can occur.
Changes in protein conformation distort glycan processing
While many of the PNGS-deletion mutants displayed modest changes in glycosylation, 
some displayed larger than expected differences that could not be rationalized by cluster 
effects. One explanation is that either the Asn→Ala mutation, or loss of the glycan, induces 
protein misfolding, leading to altered glycan processing. To test this possibility ELISAs 
were performed using b12, a CD4bs conformation-dependent antibody (Fig. 3; 
Supplementary Table 3). The binding of the majority of the PNGS-mutants was unchanged 
relative to wild-type, with the exception of N262A and N386A, which displayed 
significantly reduced binding plateaus. The N262A mutation in particular showed a dramatic 
change in glycan processing, and this effect was replicated when the N262 site was deleted 
across a small cross-clade panel (Supplementary Table 4). Reduced binding was also seen 
for the N262A and N386A mutants with a second conformation-dependent antibody, 17b, 
which additionally lost binding to the N130A mutant (Fig. 3), presumably through 
alterations to the structure of the V1 loop20,40. These three mutants displayed greater levels 
of aggregation by Western blotting (Supplementary Fig. 4), supporting the hypothesis that 
they exhibit a degree of misfolding.
Misfolding of the N130A, N262A and N386A mutants could explain the disproportionately 
large changes observed in their glycan processing (Fig. 1d). In contrast the significant 
changes observed for the N295, N339, N356, N392 and N448 mutants are likely to arise 
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from disruption of glycan clusters leading to improved accessibility by ER and Golgi α-
mannosidases.
Effect of PNGS mutation of the N332 site of vulnerability
A number of bnAbs have been isolated which incorporate the N332 glycan as part of their 
epitope. This so-called ‘supersite’ of immune vulnerability occupies a central location in the 
outer domain and lies within a high density of glycans (Fig. 4 and 5a)20. Previous studies 
have indicated this site is occupied by oligomannose-type glycans1,5,6, suggesting that steric 
constraints restrict glycan processing at this site. To understand these steric constraints, we 
studied the location of the N332 glycan on the high-resolution BG505 SOSIP.664 trimer 
structure21 and modelled how it would appear to α1,2-mannosidase, the enzyme that 
initiates glycan processing (Fig. 4). The analysis was based on the glycan conformation of 
position N332 as revealed by the PGT128 co-crystal structure17. This revealed that the high 
density of glycans clustered around N332 provide significant steric constraints that impede 
access to the terminal mannose residues of N332 by α1,2-mannosidase. In addition to the 
constraints created by neighboring glycans, the variable V1 and V4 loops, which project 
away from the trimer surface, may constitute additional obstacles (Fig. 4c-e).
The high density of glycans in this region raises the question of what effect loss of nearby 
glycans could have on the processing of the N332 glycan and, importantly, how this may 
affect recognition by bnAbs. To address this, a tryptic glycopeptide containing the N332 site 
(QAHCNLSR) was isolated by reverse-phase high performance liquid chromatography (RP-
HPLC) fractionation and analyzed by matrix-assisted laser desorption/ionization-mass 
spectrometry (MALDI-MS) to determine the glycoforms present. The MALDI MS/MS 
spectrum of the glycopeptide is shown in Supplementary Fig. 5a. Consistent with its 
structurally constrained location and previous studies, the glycan structures identified at this 
site were found to be exclusively Man8GlcNAc2 and Man9GlcNAc2, with 35% and 65% 
abundances, respectively (Fig. 5b,c). No smaller oligomannose structures or complex-type 
glycans were detected. The reproducibility of this method is demonstrated in Supplementary 
Fig. 5b. To determine if nearby sites played a role in determining the glycan structures 
present at N332, the same tryptic glycopeptide was purified and analyzed from the N301A, 
N295A, N339A, N392A and N448A mutants. The MALDI mass spectra of these profiles 
demonstrated an altered distribution of glycoforms, with Man9GlcNAc2 being lost in favor 
of Man8GlcNAc2 (Fig. 5b,c). In line with its close proximity to N332, loss of the N295 
glycan was found to have the largest impact on processing at the N332 site, resulting in an 
almost complete conversion of Man9GlcNAc2 to Man8GlcNAc2. Loss of the N301 glycan, 
which reaches over the gp120 surface towards N332, also caused a distinct loss of 
Man9GlcNAc2 at the N332 site, and smaller changes were also observed for the N339A and 
N392A mutants. It is likely that the influence of the N448 glycan is mediated through the 
N295 glycan with which it is clustered.
These observations demonstrate that the environment of a glycan is important in modulating 
its level of processing. However, at least for the N332 site, the density of surrounding 
glycans is sufficiently high to act as a buffer for single PNGS-deletions, limiting the effect 
on processing to minor re-distributions in oligomannose-type structures.
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To determine if changes to the glycan shield observed upon glycosylation site deletion could 
affect antibody recognition, the panel of gp120BaL PNGS-mutants was screened for binding 
to the N332-dependent bnAbs: 2G12, PGT121, PGT128 and PGT135 (Fig. 6; 
Supplementary Table 3 gives the IC50 values). Consistent with previous reports13,15,41,42, 
2G12 binding was reduced in the N332A, N295A, N386A and N392A mutants. The loss of 
N295 and N392 were found to be most detrimental to binding, and these glycans have been 
shown in a 2G12 Fab2 complex with HIV Env to bind within the conventional VH/VL 
binding site42. Interestingly, the effect of the N332-knockout was very modest, and this 
glycan was shown to bind within the novel secondary VH/VH’ interface formed by domain 
exchange in the complex. The loss of N332 was tolerated less well by the PGT antibodies 
with deletion of known secondary sites also causing reduced binding. Binding by PGT121, 
which recognizes both oligomannose- and complex- type glycans19,26, was robust across the 
remaining panel of mutants with the exception of N262A and N130A which, as discussed 
above, is a likely consequence of altered protein conformation. Interestingly, the observation 
that N386A mutation retained binding to PGT121 indicates that perturbations in folding may 
be localized. In contrast, PGT128 binding appeared to be modestly reduced upon loss of the 
N295, N386 and N392 sites, which were not contacted by PGT128 in the crystal structure of 
the antibody-eODmV3 complex17. Glycan array data, and the extensive contacts made by 
PGT128 with the terminal mannose residues of the D1 and D3 arms, support a preferred 
specificity for Man8GlcNAc2 and Man9GlcNAc2 glycans. The decrease in PGT128 binding 
upon mutation of the N295, N386 and N392 sites may be due to changes in glycan 
processing or flexibility at the N332/N301 epitope. The observation that N295A retains 
Man8GlcNAc2 glycans at N332 (Fig. 5) suggests a role for changes in glycan flexibility for 
this mutant or altered processing at N301.
Binding of PGT135 was significantly reduced in the N332A and N392A mutants, consistent 
with their observed roles in antibody binding20. Loss of the N295 site, which has been found 
to be important in a strain-dependent manner, was tolerated in gp120BaL, although loss of 
N386 slightly decreased binding. Additionally, the N339 glycan was also implicated in 
formation of the PGT135 epitope, either directly or indirectly (Fig. 6). Glycan array data for 
PGT135, and neutralization of pseudovirus with altered glycosylation profiles, suggests that 
there is a preference for Man7GlcNAc2 and Man8GlcNAc2 glycans at certain sites. 
Therefore removal of bystander glycan sites that impact the oligomannose structures within 
the PGT135 epitope could impact binding20.
Overall, these results show that processing of gp120 glycans are influenced by their 
environment, with removal of neighboring sites influencing the abundance of different 
glycan structures present. Such bystander effects were observed at the N332 site, which 
could explain the dependence of some bnAbs on additional glycan sites not thought to be 
directly contacted by bnAbs.
Effect of PNGS deletion on virus neutralization
To test the impact of glycan site removal on glycan processing in the context of the HIV-1 
envelope trimer, we made several BaL pseudoviruses, each with a single PNGS removed 
(N130, N262, N295, N301, N332, N386 and N392). The impact of these glycan deletions on 
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neutralization by our panel of N332-dependent bnAbs and b12 was then analyzed (Fig. 7). 
Neutralization by b12 was unaffected for the N130A, N295A, N332A, and N392A mutants. 
However, the N301A and N386A mutants displayed increased sensitivity, consistent with 
previous observations that removal of these glycans exposes the CD4bs3. An increased 
sensitivity was also observed for the N262A mutant, which could similarly arise from local 
changes in protein conformation increasing accessibility to the CD4bs. The N262A mutant 
was also more sensitive to several of the N332-dependent bnAbs, indicating increased 
accessibility of these epitopes. The effects of the N130A mutation on neutralization were 
subtler than observed for the gp120 monomer binding, possibly reflecting differences in the 
assays or, conceivably, the differences in the presentation of that site between monomeric 
gp120 and virion-associated gp120. However, reduced plateaus were observed for PGT128 
and PGT130, which could be a consequence of either altered epitope conformation or 
glycosylation composition.
Loss of glycan sites known to form bnAb epitopes resulted in reduced neutralization (e.g. 
N332A for PGT128 and 2G12, N301A for PGT128 and PGT130, N295A for 2G12, N386A 
for 2G12 and PGT135, and N392A for 2G12 and PGT135). The N332A mutation had a 
more limited impact on neutralization by PGT130 and PGT121, arising from the ability of 
these bnAbs to bind adaptably to the mannose patch and utilize alternative glycans in the 
absence of the N332 glycan30. Interestingly bnAbs PGT128, PGT130 and PGT135 were 
unable to neutralize the wild-type virus to 100%, which could indicate the presence of 
glycoforms that they are unable to bind. In contrast, PGT121, which has been shown to 
recognize both complex- and oligomannose-type glycans19,26, was able to neutralize 100% 
of the wild-type virus. The N295A mutation was tolerated to varying degrees by the bnAbs, 
and broadly correlated with the results of the gp120 monomer; neutralization by PGT121 
and PGT135 was maintained, while reduced plateaus were observed for PGT128 and 
PGT130.
Discussion
With the emergence of a large number of glycan-reactive bnAbs, it has become apparent that 
the ‘non-self’ oligomannose patch within gp120 represents an immunogenic region that 
could be exploited for vaccine design32. This study has demonstrated the persistence of the 
oligomannose population in the face of glycan-site deletion which, given the shifting nature 
of the HIV-1 glycan shield33,34, is an important requirement for ensuring the breadth and 
potency of a bnAb response. The minimal disruption to processing observed upon deletion 
of PNGSs suggests that the density of glycans on gp120 is sufficiently high to tolerate 
individual losses. However it remains to be determined whether there is a critical number of 
deletions that would reduce the density sufficiently to trigger a larger scale conversion of 
oligomannose-type glycans to complex-type glycans, and whether or not this is a realistic 
prospect in native virus given that many sites bearing oligomannose glycans are highly 
conserved (Fig. 1b and 1c). It is possible that this answer may vary between different 
isolates, depending on their base level of glycan density.
It is also important to note that additional glycan–glycan and glycan–protein interactions 
exist within the context of the trimer. By using monomeric gp120 we have focused our study 
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on the integrity of the intrinsic mannose patch of the outer domain. Given the structural 
similarity of the outer domain in the context of monomer and trimer, and the conservation of 
the epitopes of many glycan-dependent antibodies, we suggest that there are also shared 
rules governing the formation of the intrinsic-mannose patch in monomers and trimers. 
Although the precise structural factors shaping the formation and stability of trimer 
glycosylation requires investigation7,8, we predict that trimerization will only serve to 
further stabilize glycan processing.
A number of the best characterized glycan-binding bnAbs to date have been found to 
specifically target the N332 glycan9,17,19-21, although it is now believed that the area of 
vulnerability extends across Env11,12,16,24,25,43. However, N332 is central to the intrinsic 
mannose patch and we therefore focused our analysis of PNGS-deletions on the processing 
of glycoforms at the N332 site, and the consequences for bnAb binding and neutralization. 
The removal of a single glycan site was found to have a very modest effect on the glycan 
structures at the N332 site, and this was reflected in the apparent tolerance of a panel of 
N332-dependent bnAbs to these mutations. The glycan at the N295 site which, when 
deleted, had the biggest impact on N332 glycan-processing, was an exception. The reduced 
neutralization displayed by PGT128 and PGT130, which do not directly recognize the N295 
glycan, most likely reflects a more widespread perturbation in glycan processing to 
structures exhibiting reduced antibody binding.
These results provide several important considerations for vaccine design. Firstly, a question 
that remains to be answered relates to whether a successful immunogen should contain 
epitopes bearing a more restricted population of glycan structures, in order to generate the 
most potent response possible, or whether the presence of a more diverse selection of 
glycoforms would promote a polyclonal response that offers increased breadth. A better 
understanding of the glycan specificity of bnAbs would help to address this question, as well 
as site-specific glycan analysis of the functional envelope spike. Secondary to this, it is 
important to consider how to generate the desired glycoforms on a site-specific basis. Data 
presented here suggest that in order to reproduce the target epitopes in an immunogen 
context, it will be necessary to consider the wider environment of the key glycan sites, 
particularly for oligomannose sites that depend upon a high density of glycans to restrict 
glycan processing. This study has highlighted important regions of glycan–glycan packing 
that contribute to maintenance of the oligomannose population, and it is likely that their 
presence will be necessary to reproduce it in an immunogen context. Our results 
demonstrate that the presence or absence of individual sites can regulate the precise type of 
oligomannose structures produced. For example, the levels of the Man9GlcNAc2 were found 
to be particularly sensitive to PNGS-deletion, and thus with careful immunogen design it 
may be possible to precisely fine-tune the degree of glycoform heterogeneity at relevant 
sites.
One site of note that could emerge as a site of vulnerability is N262 which is almost 100% 
conserved (Fig. 1c) and has been shown to be occupied by oligomannose-type glycans137. 
Previous studies involving knockout of this glycan have shown it has an important role for 
infectivity10,44-46. While our BaL N262A pseudovirus was still infectious, increased 
sensitivity to b12 neutralization was indicative of an altered protein conformation, which 
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was supported by observations of the recombinant N262A gp120BaL. In the crystal structure 
of the BG505 SOSIP.664 trimer21, the N262 glycan makes extensive contacts with the 
protein backbone, rationalizing both its protection from endoglycosidase cleavage and its 
occupation by oligomannose-type glycans. Such a stabilizing role was also observed in a 
more recent structure of fully-glycosylated gp120 monomer47. Oligomannose-type glycans 
have previously been reported in sites that are inaccessible to glycosidases48,49, and under-
processed glycans often contribute to protein fold stability50. The requirement of this glycan 
is also highlighted by studies with antiviral carbohydrate-binding agents such as cyanovirin-
N and Griffithsin, which target oligomannose-type glycans. Resistance profiling with these 
agents consistently selects for PNGS-deletion mutants, which mostly map to sites known to 
contain oligomannose glycans including N332, N295, N339, N386, N392 and N448, 
however deletion of N262 is rarely observed51-55.
The presence of oligomannose-type glycans on Env has consequences beyond antibody 
recognition, for example through their interactions with cellular receptors of the immune 
system. One of the best characterized interactions occurs with the Dendritic Cell-Specific 
Intercellular adhesion molecule-3 (ICAM)- Grabbing Non-integrin (DC-SIGN) receptor on 
DCs in the mucosal tissues, which facilitates the trans-infection of CD4+ CCR5+ T cells in 
secondary lymphoid tissues56-58. However more relevant, perhaps, from a vaccine design 
perspective are observations that oligomannose-type glycans can induce secretion of the 
immunosuppressive cytokine, IL-10, through interaction with receptors on monocyte-
derived DCs59. Such an interaction may contribute to the poor immunogenicity of HIV-1 
Env as a vaccine candidate, and indeed it has been shown that enzymatic removal of gp120 
mannose residues, or occlusion using Griffithsin, improves the immunogenicity of 
recombinant gp120 (ref.60,61). Thus an effective vaccine strategy may have to balance the 
requirement for faithful replication of bnAb epitopes with the immunogenic properties of 
vaccine candidates.
In summary, we have shown that the conservation of the oligomannose patch, and its 
resilience in the face of glycan-site deletion, makes it a robust target for vaccine design. 
Multiple bnAbs have been isolated which display subtly different, yet overlapping, epitopes 
within this region, suggesting that the induction of a polyclonal response against it would 
protect against a diverse viral swarm. Furthermore, data presented here on the persistence of 
the mannose patch provide important insights for the design of future candidate 
immunogens.
Methods
Site-directed mutagenesis
The cloning of gp120BaL into the pHLsec expression vector has previously been 
described62. Individual knockout of all 23 PNGSs of BaL gp120 was performed by mutating 
asparagines (within the sequence Asn-X-Ser/Thr, where X is any amino acid except proline) 
to alanine. Mutagenesis was performed by the overlap extension PCR method63, using 
approximately 1 ng of WT pHLsec.BaL as the template DNA. A list of primers used is 
given in Supplementary Table 5. The full Env sequence for each construct was verified by 
DNA sequencing. Mutations in the full-length envelope were made using site-directed 
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mutagenesis and the sequences were verified by DNA sequencing. A list of primers used is 
given in Supplementary Table 6.
Protein expression and purification
Human embryonic kidney (HEK) 293T cells were purchased from the American Type 
Culture Collection and maintained in Dulbecco’s Modified Eagle’s Medium containing 10% 
fetal bovine serum, 50 U ml−1 penicillin, and 50 μg ml−1 streptomycin. Recombinant gp120s 
were expressed under serum free conditions, by transient transfection of expression plasmids 
using polyethylenimine (PEI) in a PEI:DNA ratio of 3.5:1 (w/w). Comparable mutants were 
expressed in parallel to avoid variation arising from fluctuating cell culture conditions. 
Transfected cultures were incubated for 3 days before supernatants were harvested and 
filtered through a 0.22 μM membrane (Millipore). Gp120 was purified by immobilized 
metal affinity chromatography using a HisTrap HP column (GE Healthcare) according to 
manufacturer’s instructions. Eluted fractions were concentrated using 50 kDa cut-off 
centrifugal spin filters (Vivaspin).
Enzymatic release of N-linked glycans
N-linked glycans were released from gp120 in-gel using PNGase F (New England Biolabs). 
His-purified gp120 was resolved by SDS-PAGE and stained with Coomassie Blue. 
Following destaining, the band corresponding to monomeric gp120 was excised and washed 
extensively with acetonitrile and water. Gel bands were then incubated with PNGase F for 
16 hours at 37°C, following manufacturer’s instructions. Released glycans were eluted from 
the gel with water and dried in a SpeedVac concentrator.
Fluorescent labelling of N-linked glycans
Released glycans were subsequently fluorescently labelled and purified as previously 
described64. Briefly, dried glycans were resuspended in 30 μl water before addition of 80 μl 
labelling mixture (comprising 30 mg ml−1 2-aminobenzoic acid [2-AA] and 45 mg ml−1 
sodium cyanoborohydride in a solution of sodium acetate trihydrate [4% w/v] and boric acid 
[2% w/v] in methanol). Samples were incubated at 80°C for 1 h then allowed to cool. Excess 
label was removed using Spe-ed Amide-2 cartridges.
HILIC-UPLC analysis of N-linked glycans
Fluorescently labelled glycans were separated by HILIC-UPLC using a 2.1 mm × 10 mm 
Acquity BEH Amide Column (1.7 μm particle size; Waters, Elstree, UK). The following 
gradient was run: time = 0 min (t=0): 22% A, 78% B (flow rate of 0.5 ml min−1); t= 38.5: 
44.1% A, 55.9% B (0.5 ml min−1); t=39.5: 100% A, 0% B (0.25 ml min−1); t=44.5: 100% 
A, 0% B; t=46.5: 22% A, 78% B (0.5 ml min−1), where solvent A was 50 mM ammonium 
formate, pH 4.4, and solvent B was acetonitrile. Fluorescence was measured using an 
excitation wavelength of 330 nm and a detection wavelength of 420 nm. Difference plots 
were generated in MATLAB (The MathWorks, Inc).
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Enzymatic digestion of released glycans
The abundance of oligomannose glycans was measured by digestion with Endoglycosidase 
H, which cleaves oligomannose-type glycans but not complex-type glycans (Endo H; New 
England Biolabs). 2-AA labelled glycans were resuspended in water and digested with Endo 
H for 16 hours at 37°C, according to manufacturer’s instructions. Digested glycans were 
cleaned using a PVDF protein-binding membrane plate prior to HILIC-UPLC analysis. The 
abundance of oligomannose-type glycans was calculated, as a relative percentage, by 
integration of the HILIC-UPLC chromatograms before and after Endo H digestion, 
following normalization. The magnitude of change was calculated as a % change in 
abundance, relative to wild-type.
Structural modelling of glycosylated Env
A model of the BaL gp120 trimer was constructed using the recently solved atomic-level 
resolution structure of a BG505 SOSIP.664 gp140 trimer (PDB accession code: 4NCO)21. 
First, atomic clashes present in the 4NCO crystal structure were relieved and missing side-
chains rebuilt, by executing 1,000 symmetric ROSETTA-fixbb simulations, selecting the 
lowest scoring model, and then running a constrained ROSETTA-relax simulation. Next, the 
BaL sequence was modeled onto the gp120 trimer structure, by running 1,000 ROSETTA-
remodel trajectories65, which included building new conformations for the variable loops, 
and then filtering the models by structural metrics. The best 15 models were considered as 
an ensemble of possible BaL gp120 trimer structures, as each model was in the top 33% of 
the 3 structural metrics Ramachandran (rama), attractive portion of the Lennard-Jones 
potential (fa_atr) and the total ROSETTA score.
Each N-linked glycosylation motif for each of the 15 models was decorated with 
Man8GlcNAc2 glycans at sites of predicted oligomannose-type glycans and with 
Man5GlcNAc2 glycans at remaining sites. GlycanRelax66 was used to approximate the 
conformational behavior of glycans in a glycoprotein context. For each model, 10 separate 
GlycanRelax trajectories of 10000 cycles of MonteCarlo trials were carried out. Each glycan 
on the gp120 was allowed to move independently throughout the GlycanRelax 
minimization. A single low energy model was chosen for the figures.
Purification of an N332 glycopeptide
Gp120 was resolved by SDS-PAGE, and the monomer excised and washed as described 
above. Reduction was carried out by addition of 10 mM Dithiothreitol in 100 mM 
ammonium bicarbonate and incubation at 65°C for 30 mins. Alkylation was subsequently 
performed by addition of 50 mM Iodoacetamide in 100 mM ammonium bicarbonate, with 
incubation at room temperature for 50 mins. Trypsin (Promega) was then added at a 
concentration of 12.5 μg ml−1 and incubated at 37°C for 16 hours. Glycopeptides were 
eluted from the gel with alternate washes of water and acetonitrile, filtered through a 0.45 
μM membrane (Whatman), and dried in a SpeedVac concentrator. After resuspension in 
0.1% TFA, the glycopeptide pool was fractionated by reverse phase-HPLC using a Jupiter 
C18 5 μm 250 × 4.5 mm column (300 Å pore size) (Phenomenex) and a Dionex U3000 LC 
system. The following gradient was run at a flow rate of 1 ml min−1, with fractions being 
collected every minute for 90 minutes: time = 0 min (t=0): 95% A, 5% B; t= 5: 95% A, 5% 
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B; t=90: 10% A, 90% B; t=95: 10% A, 90% B; t=97: 95% A, 5% B; t= 120: 95% A, 5% B, 
where solvent A was 50 mM ammonium formate, pH 4.4, and solvent B was acetonitrile. 
UV absorbance was detected at 214 and 280 nm.
Mass spectrometric analysis of glycopeptides
Glycopeptide fractions were desalted using C18 ZipTip® pipette tips, according to 
manufacturer’s instructions, before spotting onto a ground steel target plate in a solution of 
10 mg ml−1 2,5-Dihydrozybenzoic acid in 50% acetonitrile. MALDI-MS was performed 
using an Autoflex™ Speed MALDI-TOF/TOF instrument (Bruker), operated in positive ion 
mode. MS/MS was performed to confirm the peptide identity.
ELISA
Antibodies b12, 2G12, PGT121, PGT128 and PGT135 were obtained from the International 
AIDS Vaccine Initiative (IAVI, New York, NY). Microtitre ELISA plates (Corning) were 
coated with mouse anti-HIS capture antibody (2 μg mL−1 in PBS; Life Technologies) 
overnight at 4 °C. Plates were washed five times with a solution of PBS containing 0.05% 
Tween 20 (v/v) and then blocked for 1 h at room temperature with 5% non-fat milk in PBS 
+ 0.05% Tween (blocking buffer). Gp120 was then added at a concentration of 2 μg ml−1 in 
blocking buffer, followed by incubation for 1 h at room temperature. Plates were washed 
(×5) before addition of primary antibodies (b12, 17b, 2G12, PGT121, PGT128 & PGT135). 
A 1:5 dilution series was used starting at 20 μg ml−1 or 40 μg ml−1 in blocking buffer. 
Incubation was carried out at room temperature for 2 h. Plates were then washed (×5) and 
alkaline phosphatase-conjugated goat anti-human Fab secondary antibody (Thermo 
Scientific Pierce) was added as a 1:1000 dilution in blocking buffer. Plates were washed 
(×5) and then AP substrate (50 μL per well) was added. Once color had developed the OD at 
405 nm was measured.
Virus neutralization assay
To produce pseudoviruses, plasmids encoding Env were co-transfected with an Env-
deficient genomic backbone plasmid (pSG3ΔEnv) in a 1:2 ratio with the transfection reagent 
PEI (1 mg mL−1, 1:3 PEI:total DNA, Polysciences) into HEK 293T cells. Pseudoviruses 
were harvested 72 h post transfection for use in neutralization assays67. Neutralizing activity 
was assessed using a single round replication pseudovirus assay with TZM-bl target cells, as 
described previously68. Briefly, TZM-bl cells were seeded in a 96-well flat bottom plate at a 
concentration of 20,000 cells per well. The serially diluted antibody/virus mixture, which 
was pre-incubated for 1 h, was then added to the cells and luminescence was quantified 72 h 
following infection via lysis and addition of Bright-Glo™ Luciferase substrate (Promega). 
To determine IC50 values, serial dilutions of mAbs were incubated with wild-type virus or 
mutant virus and the dose-response curves were fitted using nonlinear regression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Pritchard et al. Page 13
Nat Commun. Author manuscript; available in PMC 2015 December 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Acknowledgements
We would like to dedicate this article in memory of our much valued friend and greatly admired colleague, Dr 
Chris Scanlan. We thank Dr Li Phing Liew for technical assistance, and Prof. Raymond A. Dwek, Prof. David J. 
Harvey, Dr Daryl Fernandes and Dr Holger Kramer for support and helpful discussions. L.K.P. has been supported 
by a Scholarship from the Department of Biochemistry, University of Oxford. M.C. is a Fellow of Oriel College, 
Oxford. This work was supported by International AIDS Vaccine Initiative Neutralizing Antibody Center and NAC 
CAVD grant (A.B.W., W.R.S. and M.C.), National Institute of Allergy and Infectious Diseases grants 
P01AI081625 (W.R.S.), 1UM1AI100663 (CHAVI-ID to M.C., A.B.W. and W.R.S.), the Medical Research Council 
MR/K024426/1 (K.J.D.) and MR/L009528/1 (T.A.B.), and Wellcome Trust Grant 090532/Z/09/Z (T.A.B.).
References
1. Leonard CK, et al. Assignment of intrachain disulfide bonds and characterization of potential 
glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein 
(gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990; 265:10373–82. [PubMed: 
2355006] 
2. Li Y, Luo L, Rasool N, Kang CY. Glycosylation is necessary for the correct folding of human 
immunodeficiency virus gp120 in CD4 binding. J. Virol. 1993; 67:584–8. [PubMed: 8416385] 
3. Binley JM, et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection 
and resistance to antibody neutralization. J. Virol. 2010; 84:5637–55. [PubMed: 20335257] 
4. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat. 
Med. 1998; 4:679–684. [PubMed: 9623976] 
5. Zhu X, Borchers C, Bienstock RJ, Tomer KB. Mass spectrometric characterization of the 
glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry. 2000; 39:11194–204. 
[PubMed: 10985765] 
6. Go EP, et al. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) 
reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic 
epitopes’ accessibility. J. Proteome Res. 2008; 7:1660–1674. [PubMed: 18330979] 
7. Doores KJ, et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose 
antigens. Proc. Natl. Acad. Sci. U. S. A. 2010; 107:13800–13805. [PubMed: 20643940] 
8. Bonomelli C, et al. The glycan shield of HIV is predominantly oligomannose independently of 
production system or viral clade. PLoS One. 2011; 6:e23521. [PubMed: 21858152] 
9. Walker LM, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. 
Nature. 2011; 477:466–70. [PubMed: 21849977] 
10. Lavine CL, et al. High-mannose glycan-dependent epitopes are frequently targeted in broad 
neutralizing antibody responses during human immunodeficiency virus type 1 infection. J. Virol. 
2012; 86:2153–64. [PubMed: 22156525] 
11. Scharf L, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope 
spike. Cell Rep. 2014; 7:785–95. [PubMed: 24767986] 
12. Huang J, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–
gp120 interface. Nature. 2014; 515:138–142. [PubMed: 25186731] 
13. Scanlan CN, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 
2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 2002; 
76:7306–7321. [PubMed: 12072529] 
14. Sanders RW, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human 
immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002; 76:7293–7305. [PubMed: 
12072528] 
15. Calarese, D. a, et al. Antibody domain exchange is an immunological solution to carbohydrate 
cluster recognition. Science. 2003; 300:2065–71. [PubMed: 12829775] 
16. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new 
HIV-1 vaccine target. Science. 2009; 326:285–9. [PubMed: 19729618] 
17. Pejchal R, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV 
glycan shield. Science. 2011; 334:1097–103. [PubMed: 21998254] 
Pritchard et al. Page 14
Nat Commun. Author manuscript; available in PMC 2015 December 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
18. McLellan JS, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody 
PG9. Nature. 2011; 480:336–43. [PubMed: 22113616] 
19. Mouquet H, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV 
antibodies. Proc. Natl. Acad. Sci. U. S. A. 2012; 109:E3268–77. [PubMed: 23115339] 
20. Kong L, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope 
glycoprotein gp120. Nat. Struct. Mol. Biol. 2013; 20:796–803. [PubMed: 23708606] 
21. Julien J-P, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013; 
342:1477–83. [PubMed: 24179159] 
22. Pancera M, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-
directed antibody PG16. Nat. Struct. Mol. Biol. 2013; 20:804–13. [PubMed: 23708607] 
23. Julien J-P, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody 
PG9. Proc. Natl. Acad. Sci. U. S. A. 2013; 110:4351–6. [PubMed: 23426631] 
24. Blattner C, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-
gp120 interface on intact HIV-1 Env trimers. Immunity. 2014; 40:669–80. [PubMed: 24768348] 
25. Falkowska E, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the 
prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014; 40:657–68. 
[PubMed: 24768347] 
26. Julien J-P, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via 
recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013; 
9:e1003342. [PubMed: 23658524] 
27. Sok D, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of 
gp120 broadens neutralization of HIV. Sci. Transl. Med. 2014; 6:236ra63.
28. Sok D, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 
family of broadly neutralizing HIV antibodies. PLoS Pathog. 2013; 9:e1003754. [PubMed: 
24278016] 
29. Mascola JR, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV 
chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000; 6:207–10. 
[PubMed: 10655111] 
30. Hessell AJ, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection 
against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009; 
5:e1000433. [PubMed: 19436712] 
31. Moldt B, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective 
protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U. S. A. 2012; 
109:18921–5. [PubMed: 23100539] 
32. Burton DR, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012; 12:396–407. 
[PubMed: 23084910] 
33. Wei X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003; 422:307–12. [PubMed: 
12646921] 
34. Moore PL, et al. Evolution of an HIV glycan – dependent broadly neutralizing antibody epitope 
through immune escape. Nat. Med. 2012; 18:1688–1692. [PubMed: 23086475] 
35. Cutalo JM, Deterding LJ, Tomer KB. Characterization if glycopeptides from HIV-1 SF2 gp120 by 
liquid chromatography mass spectrometry. J. Am. Soc. Mass Spectrom. 2004; 15:1545–1555. 
[PubMed: 15519221] 
36. Go EP, et al. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J. Proteome 
Res. 2009; 8:4231–4242. [PubMed: 19610667] 
37. Pabst M, Chang M, Stadlmann J, Altmann F. Glycan profiles of the 27 N-glycosylation sites of the 
HIV envelope protein CN54gp140. Biol. Chem. 2012; 393:719–30. [PubMed: 22944675] 
38. Go EP, et al. Characterization of host-cell line specific glycosylation profiles of early transmitted/
founder HIV-1 gp120 envelope proteins. J. Proteome Res. 2013; 12:1223–34. [PubMed: 
23339644] 
39. West AP, et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify 
potential functional epitope residues. Proc. Natl. Acad. Sci. U. S. A. 2013; 110:10598–603. 
[PubMed: 23754383] 
Pritchard et al. Page 15
Nat Commun. Author manuscript; available in PMC 2015 December 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
40. Kwong PD, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 
receptor and a neutralizing human antibody. Nature. 1998; 393:648–59. [PubMed: 9641677] 
41. Trkola A, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on 
the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996; 70:1100–8. 
[PubMed: 8551569] 
42. Murin CD, et al. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 
Env by negative-stain single particle electron microscopy. J. Virol. 2014; 88:10177–10188. 
[PubMed: 24965454] 
43. Chuang G-Y, et al. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of 
diverse viral strains. J. Virol. 2013; 87:10047–58. [PubMed: 23843642] 
44. Willey RL, et al. In vitro mutagenesis identifies a region within the envelope gene of the human 
immunodeficiency virus that is critical for infectivity. J. Virol. 1988; 62:139–47. [PubMed: 
3257102] 
45. François KO, Balzarini J. The highly conserved glycan at asparagine 260 of HIV-1 gp120 is 
indispensable for viral entry. J. Biol. Chem. 2011; 286:42900–10. [PubMed: 22006924] 
46. Wang W, et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on 
infectivity and antibody-mediated neutralization. Retrovirology. 2013; 10:14. [PubMed: 
23384254] 
47. Kong L, Wilson IA, Kwong PD. Crystal structure of a fully glycosylated HIV-1 gp120 core reveals 
a stabilizing role for the glycan at Asn262. Proteins Struct. Funct. Bioinforma. 2015; 83:590–596.
48. Crispin MDM, et al. Monoglucosylated glycans in the secreted human complement component C3: 
implications for protein biosynthesis and structure. FEBS Lett. 2004; 566:270–4. [PubMed: 
15147907] 
49. Crispin M, et al. Structural Plasticity of the Semliki Forest Virus Glycome upon Interspecies 
Transmission. J. Proteome Res. 2014; 13:1702–1712. [PubMed: 24467287] 
50. Gala, F. a; Morrison, SL. The role of constant region carbohydrate in the assembly and secretion of 
human IgD and IgA1. J. Biol. Chem. 2002; 277:29005–11. [PubMed: 12023968] 
51. Balzarini J, et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to 
human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. 
Virol. 2006; 80:8411–21. [PubMed: 16912292] 
52. Witvrouw M, et al. Resistance of human immunodeficiency virus type 1 to the high-mannose 
binding agents cyanovirin N and concanavalin A. J. Virol. 2005; 79:7777–7784. [PubMed: 
15919930] 
53. Hu Q, Mahmood N, Shattock RJ. High-mannose-specific deglycosylation of HIV-1 gp120 induced 
by resistance to cyanovirin-N and the impact on antibody neutralization. Virology. 2007; 368:145–
54. [PubMed: 17658575] 
54. Alexandre KB, et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and 
sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology. 2010; 402:187–96. 
[PubMed: 20392471] 
55. Huang X, Jin W, Griffin GE, Shattock RJ, Hu Q. Removal of two high-mannose N-linked glycans 
on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding 
agent griffithsin. J. Gen. Virol. 2011; 92:2367–73. [PubMed: 21715597] 
56. Geijtenbeek TB, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances 
trans-infection of T cells. Cell. 2000; 100:587–97. [PubMed: 10721995] 
57. Kwon DS, Gregorio G, Bitton N, Hendrickson W. a, Littman DR. DC-SIGN-mediated 
internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 2002; 
16:135–44. [PubMed: 11825572] 
58. Hong PW, et al. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and 
primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding 
sites: implications for structural analyses of gp120-DC-SIGN binding. J. Virol. 2002; 76:12855–
12865. [PubMed: 12438611] 
59. Shan M, et al. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. 
PLoS Pathog. 2007; 3:e169. [PubMed: 17983270] 
Pritchard et al. Page 16
Nat Commun. Author manuscript; available in PMC 2015 December 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
60. Banerjee K, et al. Enzymatic removal of mannose moieties can increase the immune response to 
HIV-1 gp120 in vivo. Virology. 2009; 389:108–21. [PubMed: 19410272] 
61. Banerjee K, et al. Occluding the mannose moieties on human immunodeficiency virus type 1 
gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res. Hum. 
Retroviruses. 2012; 28:206–14. [PubMed: 21793733] 
62. Dunlop DC, et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV 
antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. 
Glycobiology. 2010; 20:812–23. [PubMed: 20181792] 
63. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap 
extension using the polymerase chain reaction. Gene. 1989; 77:51–9. [PubMed: 2744487] 
64. Neville DCA, Dwek RA, Butters TD. Development of a single column method for the separation 
of lipid- and protein-derived oligosaccharides. J. Proteome Res. 2009; 8:681–687. [PubMed: 
19099509] 
65. Huang P-S, et al. RosettaRemodel: a generalized framework for flexible backbone protein design. 
PLoS One. 2011; 6:e24109. [PubMed: 21909381] 
66. Pancera M, et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope 
architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 2010; 107:1166–
71. [PubMed: 20080564] 
67. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase 
reporter gene assays. Curr. Protoc. Immunol. 2005 Chapter 12, Unit 12.11. 
68. Walker LM, et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 
neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. 
U. S. A. 2011; 108:20125–9. [PubMed: 22123961] 
69. Bowden, T. a, et al. Chemical and structural analysis of an antibody folding intermediate trapped 
during glycan biosynthesis. J. Am. Chem. Soc. 2012; 134:17554–63. [PubMed: 23025485] 
70. Harvey DJ, et al. Proposal for a standard system for drawing structural diagrams of N- and O-
linked carbohydrates and related compounds. Proteomics. 2009; 9:3796–801. [PubMed: 
19670245] 
Pritchard et al. Page 17
Nat Commun. Author manuscript; available in PMC 2015 December 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Contribution of individual glycans to the total glycosylation of gp120BaL
(a) HILIC-UPLC profile of N-linked glycans released from gp120BaL. The Man5-9GlcNAc2 
series is labelled M5–M9 and highlighted in blue. Remaining peaks correspond to hybrid 
and complex-type glycans (b) Schematic showing the distribution of the 23 PNGSs of 
gp120BaL. Sites were allocated as putative complex-type or putative oligomannose-type 
based on previous reports1,35-37. (c) Percentage conservation of the individual PNGSs across 
different clades, based on analysis of over 4000 aligned Env sequences from the Los Alamos 
HIV sequence database (http://www.hiv.lanl.gov/). (d) Effect of PNGS-deletion on the total 
abundance of oligomannose-type glycans, and the individual abundance of Man9GlcNAc2. 
Values were obtained by integration of corresponding HILIC-UPLC peaks (Supplementary 
Fig. 2), before and after Endoglycosidase H treatment, and represent the percentage change 
in abundance (relative to wild-type). Percentage change = [(% oligomannose in wild-type − 
% oligomannose in mutant)/(% oligomannose in wild-type)] × 100. Values are reported in 
Supplementary Table 2. The dashed line represents the predicted drop in oligomannose 
levels from the elimination of one site containing only oligomannose-type glycans.
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Figure 2. Role of glycan clusters in maintaining the oligomannose population
(a) Model of a fully glycosylated BaL trimer based on the reported gp140 trimer crystal 
structure21 (PDB accession code: 4NCO). Modelled glycans are shown as sticks. The 
surface of the glycans and underlying protein are depicted in shades of gray. Man5GlcNAc2 
glycans were modelled at sites of predicted complex-type glycans and Man8GlcNAc2 
glycans were added at predicted oligomannose sites. (b) A close-up view of the gp120 
monomer. Glycans are colored according to the effect of their elimination on total 
Man9GlcNAc2 levels or complex-type glycosylation according to Fig 1d. A change of over 
5% is greater than the intrinsic variation of glycosylation (Supplementary Fig. 1; 
Supplementary Table 1). (c) Examples of changes in glycan composition upon deletion of 
individual glycan sites of the mannose patch. Residual plots were calculated by the 
subtraction of HILIC-UPLC spectra of PNGS-deletion mutants from that of the wild-type. 
Peaks corresponding to oligomannose-type glycans are highlighted. Man5-9GlcNAc2 (M5–
9) are schematically labelled according to the combined nomenclature69 of Harvey et al70 
and the Center of Functional Glycomics.
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Figure 3. Recognition of PNGS-deletion mutants by conformation-dependent antibodies
Binding of the conformation-dependent monoclonal antibodies b12 and 17b was tested 
against the panel of gp120BaL PNGS-deletion mutants by capture ELISA. Error bars 
represent standard deviation. Each experiment was performed in duplicate and repeated 
three times.
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Figure 4. Steric barriers to the processing of Env glycans
The α-mannosidase enzyme has impeded access to the terminal sugars of the mannose patch 
due to steric constraints imposed by both protein and glycan moieties. (a) The high-
resolution structure of α1,2-mannosidase (PDB accession code: 2RI9) bound to a 
disaccharide substrate shows how the substrate binds in a deep, concave pocket. (b) When 
the α-1,2-mannosidase structure is docked onto the surface of the HIV-1 Env trimer (hybrid 
model of EMD-5779 and PDB 3TYG) and aligned on the terminal D1, D2, or D3 arms of 
the Man9GlcNAc2 moiety at position N332, there are significant clashes (c-e). In those three 
panels, the colored surfaces represent areas of the trimer that are within 2 Å of α-1,2-
mannosidase after docking the terminal mannoses on Man9GlcNAc2 into the binding 
enzyme pocket, i.e., clashes occur that impede enzyme access to its glycan substrates and 
are therefore predicted to prevent glycan processing. The variable loops V4 and V1 account 
for a large proportion of the clashes seen in panels d and e, respectively.
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Figure 5. The effect on processing at the N332 glycosylation site by the deletion of neighboring 
glycans
(a) Model of the N332 glycan (green sticks) on the outer domain surrounded by neighboring 
(dark blue sticks) and distant glycans (gray sticks). (b) Site-specific glycan analysis of the 
N332 site from a panel of mutants lacking the neighboring glycans (Panel A; dark blue 
glycans). A tryptic glycopeptide containing the N332 site (QAHCNLSR) was isolated and 
analyzed by MALDI-MS to determine the glycoforms present. The same glycopeptide was 
analyzed from gp120BaL mutants carrying PNGS-deletions proximal to N332. (c) 
Quantitation of the abundance of Man9GlcNAc2 on the wild-type and mutant glycopeptides 
as determined by MALDI-MS. Symbols as in Fig. 2.
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Figure 6. Recognition of glycan site deletion mutants by N332-specific bnAbs
Binding of a panel of N332-specific bnAbs, including 2G12, PGT128, PGT135 and 
PGT121, was tested against the panel of gp120BaL glycan site deletion mutants by capture 
ELISA. Error bars represent standard deviation. Each experiment was performed in 
duplicate and repeated three times.
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Figure 7. The effect of glycan site deletion on neutralization by N332-specific bnAbs
Neutralization of the BaL wild-type virus and mutant viruses by b12 and N332-specific 
bnAbs, including PGT121, PGT135, 2G12, PGT128 and PGT130. Error bars represent 
standard deviation. Each experiment was performed in duplicate and repeated three times.
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